SecBot SecBot
10-K/A ·Filed Mar 27, 2026

INVA

Innoviva, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001193125-26-128939
Amended annual report (potential restatement)
Actionable Insight • Neutral

This is a routine procedural amendment to comply with SEC reporting requirements for significant subsidiaries. Traders should note that the inclusion of Armata's financials provides additional transparency into the financial health of Innoviva's primary investment, but does not signal any change in Innoviva's own operations, strategy, or financial condition. No trading action is warranted based on this filing alone.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.91
T+0 close · Mar 27, 2026 · via day close
Latest settled
+1.92%
T+60 · $23.35
Vs SPY
−14.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $22.91entry
  2. T+1 · 8mo ago +1.70%α −1.19% · $23.30
  3. T+5 · 7mo ago +1.61%α −2.69% · $23.28
  4. T+20 · 7mo ago +3.40%α −9.19% · $23.69
  5. T+60 · 5mo ago +1.92%α −14.57% · $23.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Innoviva, Inc. filed an amended 10-K to include the audited consolidated financial statements of its majority-owned subsidiary, Armata Pharmaceuticals, Inc., which were not available at the time of the original filing. The amendment is routine and does not reflect changes to Innoviva's own financial statements or operations.

Key Facts

  • The 10-K/A filing is an amendment to include Armata Pharmaceuticals' audited financial statements as required by Rule 3-09 of Regulation S-X.
  • Armata is a clinical-stage biotechnology company focused on bacteriophage therapeutics, in which Innoviva holds a 68.8% ownership stake.
  • The amendment was necessary because Armata's financial statements were not available when the original 10-K was filed on February 25, 2026.
  • The explanatory note confirms that no other disclosures in the original filing have been updated or changed.
  • The filing includes new certifications from Innoviva's CEO and CFO dated March 27, 2026, as required by SEC rules.

Financial Impact

No direct financial impact to Innoviva; the amendment is procedural and relates to subsidiary reporting requirements.

none

Risk Factors

  • Armata's financial statements reveal substantial doubt about its ability to continue as a going concern, with only $8.7 million in cash as of December 31, 2025, which may raise concerns about the valuation of Innoviva's investment.
  • Armata reported a significant net loss of $173.8 million in 2025, which could impact the carrying value of Innoviva's investment if further impairments are recognized.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
10-K/A Filing (Primary)0001193125-26-128939
Document: inva-20251231.htm0001193125-26-128939
Document: inva-ex32.htm0001193125-26-128939
Document: inva-ex31_1.htm0001193125-26-128939
Document: inva-ex31_2.htm0001193125-26-128939
Document: inva-ex23_3.htm0001193125-26-128939
Document: 0001193125-26-128939-index-headers.html0001193125-26-128939
Document: 0001193125-26-128939-index.html0001193125-26-128939
Document: 0001193125-26-128939.txt0001193125-26-128939

Track record

5 reports on INVA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $19.24 to $18.97 Now $18.49 +3.90% ▲ +1.40% +4.69% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $21.12 to $21.26 Now $18.49 −12.45% ▲ +0.66% +1.38% vs SPY
  3. May 18, 202626w ago 8-K Neutral 3/10 Entry $21.73 to $22.13 Now $18.49 −14.91% ▲ +1.84% −0.46% vs SPY
  4. May 6, 202627w ago 8-K Mixed 5/10 Entry $22.80 to $23.14 Now $18.49 −18.90% ▲ +1.49% −0.01% vs SPY
  5. Mar 27, 202633w ago 10-K/A Neutral 3/10 Viewing Entry $22.91 to $23.28 Now $18.49 −19.29% ▲ +1.61% −2.69% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026